International Journal of Pharmacy and Herbal Technology
e-ISSN: 2583-8962 Vol. 2, Issue 4 (October – December, 2024) pp: (2853-2867)
IJPHT Journal
Papers Having Good Impact

Liposome as Pharmaceutical Carriers: An In-Depth Review on Formulation and Characterization of Liposomes

Madhuri K. Pawar [*], Shirish B. Nagansurkar, Sanjay K. Bais
Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India
[*]Corresponding Author: pawarmadhuri2611@gmail.com

Received Date: November 29, 2024; Published Date: 27 December,2024

Abstract
This article provides a thorough introduction to liposomes, highlighting their special qualities, formulation methods, and numerous uses in drug administration and biomedical research. Due to their biocompatibility, ability to encapsulate a variety of therapeutic substances, and potential for targeted treatment, liposomes, as nanocarriers, give a variety of benefit. We go cover recent advances in liposome technology that improve their safety and efficacy profiles, such as surface alteration, triggered release mechanisms, and combination therapies. We also discuss the difficulties in producing stable liposomes, regulatory issues, and their changing application in new therapeutic areas such as immunotherapy and gene therapy. This review aims to provide insights into the future paths of liposome research and their revolutionary potential in personal healthcare by combining current knowledge and trends.

Keywords - Liposomes, Wound healing, amphipathic, immunogenic, sonication.

INTRODUCTION

Dr. Alec D Bangham FRS, a British hematologist from the Barham Institute in Cambridge, described liposomes in 1961. The term liposome is derived from the Greek words 'Lipos' means fat and 'Soma' mean body. Liposomes are spherical small particles made up of one or more circular lipid bilayers divided by water and an aqueous buffer compartment, with sizes ranging from 25nm to 1000nm [1,2].



***Figure 1**: Structure of Liposomes*

Liposomes

A liposome is defined "Liposome are the simple microscopic vesicles where in an aqueous volume is entirely enclosed by a membrane composed of lipid molecule." Liposomes are composed of a variety of bipolar substances. Drug molecules can be directly attached in aqueous space or incorporated into bilayers of lipid [3,4].

One of the primary cutting-edge methods for medication delivery systems is the use of liposomes. Studies on liposomes have grown in significance in the pharmacological, biological, and medical fields because liposomes are thought to be the best carriers for the introduction of many substances, including medications that treat cancer [3], antibiotics [4], fungal [5], anti-inflammatory [6], and genetically[7] In 1965 saw the approval of bilayer systems [11,12].They're circular capsules of soft material made of one or more bilayer membrane(s) that divide an aqueous medium into two or more [9] Phospholipid molecules are mostly made up of several polar heads[10] Two hydrophobic hydrocarbon chains and group [11].The polar poorly discharged or zwitterion pairs are both possible. The hydrocarbon chain molecules have different lengths and possess different degrees of unsaturation [12]. The formation of liposomes occurs spontaneously upon reconstitution of dry lipid films in an aqueous solution [13,14].

Many types of research have been carried out for the surface modification of liposomes to enhance their properties and increase their applicability to deliver the active pharmaceutical ingredients to the site of action for in vivo applications. For example, the utilization of polyethylene glycol (PEG) and polyvinyl alcohol (PVA) decreased opsonization and made the liposomes less susceptible for hepatic clearance, and consequently prolonged liposomes residence time in the systemic circulation [15]. As well, the insertion of rhodamine-123- conjugated polymer in the surface of the liposomes increased the formulation accumulation in the mitochondria [16]. The incorporation of D-a-tocopheryl polyethylene glycol 1000 succinate-triphenylphosphine conjugate (TPGS1000-TPP) to the surface of a liposomal formulation of paclitaxel improved its cellular uptake and mitochondrial targeting and consequently enhanced apoptosis processes in drug-resistant lung cancer [17]. There are a number of liposomal products such as ambisome, myocet, doxil, depoCyt, etc. approved by the FDA for commercial usage [18, 19].

Composition



Figure 2: *Liposome Composition*



Figure 3: *Classification of Liposomes*

Liposomes are mostly made up of phospholipids, specifically glycerophospholipids and sphingomyelins. Glycerophospholipids have a hydrophilic head group and a hydrophobic side chain. Head produces a variety of glycerophospholipids. Group variant, such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol, (PI), phosphatidic acid (PA), phosphatidylglycerol (PG), and cardiolipin.

Various glycerophospholipids. (CL) [20, 21]. Nonpolar moieties vary in length, creating different glycerophospholipids such dimyristoyl, dipalmitoyl, and distearoyl PC. Additionally, the bonding types an ether or ester between glycerol and aliphatic chains resulting in various glycerophospholipids. Sphingomyelins (SMs) are essential membrane components of the animal cells [22,]. Sphingosine is the backbone of SM [23].

Each molecule of SM has an average of cis-double bonds in amide connected acyl chains. Natural SMs have standard acyl lengths. Typically, longer than the paraffin residues of sphingosine, they considered asymmetric molecules [24].

Classification of Liposomes

Liposomes can be generated using a variety of methods. Their nomenclature also depends on the method of preparation, structural parameters, or the special function assigned.

Based on structure parameters	Based on method of liposome preparation
SUV-Small Unicellular vesicles (20-100nm)	REV-Single or Oligo lamellar vesicles
MUV-Medium sized Uni lamellar vesicles	MLV-REV-Multilamellar vesicles
MLV-multi-lamellar large vesicles>0.5mm	SPLV- Stable pluri-lamellar vesicles
OLV- Oligolamellar vesicles 0.1-1mm	FATMLV-Frozen & thawed MLV
LUV-Large Unilamellar vesicles >100	VET-Vesicles prepared by extrusion technique
UV-Unilamellar vesicles (All size range)	DRV-Dehydration –rehydration method
GUV-Giant Unilamellar vesicles >1mm	
MV-Multivesicular vesicles >1mm	

Table 1: *Classification of Liposomes*

Advantages

The liposome has many advantages, such p -Liposomes are biocompatible, biodegradable, non-toxic, and non-immunogenic.

Suitable for administering hydrophobic, amphipathic, and hydrophilic drugs.

Provides site avoidance and protects the encapsulated medication from the external environment.

Improved effectiveness and therapeutic index.

Improved stability by encapsulation.

Minimize hazardous medication exposure on vulnerable tissues.

Increase protein stability.

Offer sustained release.

Change the pharmacokinetics and pharmacodynamics of medicines. Articular passive targeting of cancer cells (liposomal doxorubicin).

Disadvantages

Production costs are significant.

Leakage and fusion of encapsulated drugs/molecules.

Phospholipids can oxidize and hydrolyse.

Short half-life.

Low solubility.

Lower stability.

Rapid uptake by R.E.S cells.

Potential for allergic reactions to liposomal contents.

Difficulty targeting specific tissues owing to huge size.

Methods of preparation

Mechanical dispersion method

Lipid film hydration by hand shacking
Non hand shacking or freeze drying
Micro- emulsification
Sonication
French –pressure cell
Membrane extrusion
Dried reconstituted vesicles
Freeze- Thawed liposome

Solvent dispersion method

Ethanol injection
Ether injection
Double emulsion vesicles
Reverse phase evaporation
Stable pluriglandular vesicles

Detergent removal methods: -

Detergent (chlorate)
Dialysis
Column chromatography
Dilution.
Reconstituted Sendai virus enveloped

Mechanical method of preparation

Preparation of liposomes by the thin film hydration method

The most common simply and widely applicable method for liposomes formulation is the thin-film hydration method [25]. In this technique, liposomes are prepared by dissolving the lipid in an organic solvent usually chloroform or mixtures of chloroform and methanol, and the solvent is then removed by film deposition under vacuum. After the complete evaporation of the organic solvents, the lipid residue is hydrated by using an aqueous buffer; the lipids spontaneously undergo swelling and hydration to form a liposome. This method produces liposomes with a heterogeneous sized aggregation of multilamellar vesicles over one micrometre in diameter. The particles can be downsized by using different techniques, for instance, extrusion or sonication.

Preparation of liposomes by solvent dispersion methods

Ether injection method

In this method, liposomes are prepared by dissolving the lipid in diethyl ether or a mixture of methanol and ether, followed by the slow injection to an aqueous solution of the compound to be incorporated under lower pressure or at 55–65 C. The main drawbacks of this procedure are the heterogeneous population of the obtained vesicles, and the exposure of the substances to be encapsulated to high temperature [26].

Ethanol injection method

This method involves the utilisation of ethanol to dissolve phospholipids and cholesterol. By means of a syringe pump, the resulting lipid solution is injected under stirring conditions in a definite volume of the aqueous solution. Liposomes are then spontaneously formed as soon as the lipid solution contacts the aqueous phase. The suspension of liposomes is then left under stirring at room temperature for 15 min [27]. This procedure offers numerous advantages, such as fast implementation, simplicity, and reproducibility. Also, it does not lead to oxidative alterations or

degradation of lipids and has the ability to form small unilamellar vesicles without extrusion or sonication [27, 28].

Preparation of Liposomes by methods based on fusion or size transformation of prepared the vesicle

Freeze-thaw extrusion method

Freezing and thawing method is considered to be a convenient technique for increasing the trapped capacity of the liposomal preparations since it reveals a physical disruption of the lamellar structure, likely due to the ice crystals formed during the process of freezing [29]. Liposomes prepared by the film method were vortexed with the material to be incorporated until the whole lipid film is suspended, and the resulted vesicles are frozen in warm water and vortexed again. Then extrusion of the sample is applied three times after two cycles of freeze- thaw and vertexing, followed by six cycles of freeze-thaw and additional eight extrusions [30]. Freeze-thaw cycling is a method frequently used in liposomes preparation in order to increase the encapsulation efficiency [31]

The dehydration/ rehydration method

One of the drawbacks of macrolide and aminoglycoside antibiotics liposomes is their low encapsulation efficiency, which results in preparations with lower drug content. The encapsulation efficiencies and stability (in vitro) of these antibiotics could be enhanced by dehydration/rehydration of the obtained vesicles [32]. Emptying the buffer containing small unilamellar vesicles and rehydrating it with the aqueous solution containing the compound to be incorporated after which they are dried. This led to solid lipids dispersion in small subdivided forms and the vesicles are then rehydrated. Liposomes prepared by this technique are usually oligolamellar vesicle [33, 34].

Supercritical fluid technology

The supercritical state of a fluid is intermediate between that of gas and liquids. In the pharmaceutical field, supercritical carbon dioxide (scCO2) is the most commonly used gas which can become supercritical at its critical temperature and pressure of 31.1 C, 7.38 respectively [35].

The supercritical anti-solvent method

This technique is being used to produce a micronized and homogeneous dispersion of phospholipid materials. Cholesterol and other lipid materials dissolved in an organic solvent and placed in a glass container. CO2 gas is sprayed through capillary tubes into a high- pressure precipitation vessel and as a result of a sudden change in temperature and pressure the CO2 gas transformed into a supercritical phase. Subsequently, evaporation of the organic solvent takes place and the lipids are extracted into the supercritical phase, which leads to supersaturation of the lipids in the scCO2 phase and precipitation of the lipid materials. After that, the organic solvent is removed by continuous pumping CO2 into the vessel to achieve fine lipid particles. Finally, adding the aqueous solution for liposomes formation. A previous study made a comparison between the conventional method (Bangham method) and the supercritical anti-solvent (SAS) method, it was reported that SAS method was more efficient and environmentally- friendly procedures to produce liposomes. Because it produced small particle size distribution and high entrapment efficiency and considered as an environmentally-friendly technique because it enables to apply "soft" organic solvents for example ethanol if compared with the conventional method's organic solvents (isopropyl ether, chloroform, diethyl ether and methanol). And also, the SAS process is performed under lower temperature conditions unlike the conventional Bangham method [36]. Another study used the Supercritical process for encapsulation of both eugenol (EUG) and a-lipoic acid (ALA) as an antioxidant in liposome vesicles. It was mentioned that EUG was entrapped with an overall efficiency of 86.3% with a particle size of 200nm and ALA was encapsulated

with a maximum EE of 68.1% with a particle size of 230nm and the prepared liposome exhibited a good stability for at least 40 days [37]. The previous studies did not show a significant difference in terms of the liposome size, entrapment efficiency and stability compared with the conventional Bangham method for liposome preparation except SAS process lead to complete removing of the organic solvent. To avoids the problems caused by organic solvent residues, and due to the dissolution properties of supercritical CO2, that could be used as an excellent substitute for the organic solvent, an improved Supercritical reverse phase evaporation (ISPER) method was developed in which the aqueous solution with the phospholipid materials were introduced into a sealed viewing cell. Followed by adjustment the temperature and pressure to suitable values and then introducing the CO2. After equilibration, CO2 removed, and liposomes were formed, and the liposome prepared by this method showed improvement in entrapment efficiency of glucose using alpha-dioleoyl phosphatidylcholine (DOPC) if compared by the Bangham method. Moreover, the liposome prepared by the ISPER method was highly stable for 30 days [38].In general, by comparing the SCF technique with other conventional methods for liposome preparation the SCF has provided several advantages for example, due to the use of supercritical carbon dioxide (scCO2) (non-flammable, inert, non-toxic, and more economic), SCF was considered as a green process, Possibility of large-scale production of liposome by SC Funder the good manufacturing practice (cGMP) conditions [39],finally liposome once formed no need for further processing (drying and precipitation) to achieve dry powder liposomal formulations [40].

French pressure cell

French pressure cell involves the extrusion of MLV though a small orifice in important feature of the French pressure vesicle method is that the protein does not seem to the significantly during the procedure as they are in sonication. The method involves gentle handling of unstable methods. The method has several advantages over sonication method. The resulting liposome are rather larger the sonicated SUVs. The drawbacks of the method are that the high temperature is difficult to achieve and the working volumes are comparatively small (about 50 ml as the maximum).

Reverse phase evaporation

After putting the lipid mixture to a round-bottom flask, the solvent evaporates under pressure using a rotating evaporator. Vesicles will occur if the system is cleansed with nitrogen and lipids are redissolved in the organic phase. The typical solvent of choice is diethyl ether and isopropyl ether. Once the lipids have been redissolved, the emulsion is created, the solvent is removed from the emulsion by evaporating it to a semisolid gel under reduced pressure, and the non-encapsulated material is then removed. Reverse phase evaporation vesicles (REVs) are the name given to the resultant liposome. With this technique, big macromolecules may be produced quite effectively [41, 42]. Liposome formation may be achieved by the detergent removal method. According to Isabelloto Nkanga et al. (2019), this method involves soluble phospholipids at key micelle concentrations using detergents. By column chromatography after detergent removal phospholipid molecules form themselves in dialysis bags or other suitable aqueous solution. Mix up to create liposomes (Patti et al., 2015; Akbarzadeh et al., 2013). Many elements that can affect liposomes that are produced by this method' size and homogeneity method, including the initial phospholipid to detergent ratio and the detergent rate Wagner and Vorauer-Uhl (2011) and Maherani et al. (2011) discuss elimination. The downsides of Impurities in the final liposomal can be a detergent removal method formulation, and any potential interactions between the encapsulated drug and detergent and that this method of achieving the time-consuming nature of this technique (Meure et al., 2008; Schubert, 2003).

Evaluation parameters of liposomes

For a specific objective, the liposomal formulation and processing are characterized to ensure constant in vivo and in vitro performance. Physical, chemical, and biological factors were the three categories into that the characterization variables for evaluation purposes can be divided. Size, shape, appear, and release profile are examples of physical description assessment factors. Investigations to determine the potency and purity of various lipophillic components are part of chemical description investigations. The safety and suitability of a formulation for a therapeutic application can be verified using the aid of biological description qualities. Some the parameters are: -The Vesicle shape assessed using electron Microscopic Techniques. Lamellarity of vesicles is determined by Freeze Fracture Electron Microscopy and P31 Nuclear Magnetic Resonance Analysis.

Vesicle shape and lamellarity

The Vesicle shape assessed using electron Microscopic Techniques. Lamellarity of vesicles is determined by Freeze Fracture Electron Microscopy and P31 Nuclear Magnetic Resonance Analysis.

Vesicle size &size distribution

Using photon correlation spectroscopy, the liposome size distribution was ascertained.

Microscopic Techniques Optical Microscopy

The phase-contrast, fluorescent, and bright field microscopy make up the tools utilized in the microscopic method, and are effective to determine the size of large vesicles.

CRYO-Transmission Electron Microscopy Techniques

The dimensions and forms of vesicles' surface have been defined through the utilization of this technique.

Diffraction & Scattering Techniques

Laser Light Scattering Photon correlation spectroscopy (PCS)

The study of the time dependent of intensity variation in scattered laser light resulting from Brownian motion of particles in suspension or solution. Large particles do not disperse equally as small particles are, so the rate of intensity variation in scattered light varies along these paths. Particles in the range of roughly 3 nm can be quantified using this technique which also lets one to use the Stoke-Einstein equation to determine the mean hydrodynamic size (RHSS) of the particles.

Hydrodynamic Techniques

The ultracentrifuge and gel permeation are two parts of this procedure. On separate radial MLVs from SUVs, exclusion filtration was applied on large pure gels. Large vesicles, measuring one to three millimetres in diameter, usually do not make it to the gel and end up atop the column. The conventional, quick method for estimating the size distribution of the liposome production has been substituted with a thin-film chromatography approach that uses agarose beads. But whether this process was disclosed or not as the more classic column chromatography, it is subject to a physical obstruction of the agar gel's pores.

Zeta potential determination

By detecting the electrical motion of the 90-level angle, the potential of zeta was calculated. Using the 3000 HS zeta-seizer equipment, the measurement took out in triplicate. To get ready the sample for the possible determination, it was diluted using suitable diluents.

Analytical properties for evaluation of liposomes

Properties	Analytical techniques
Size	Dynamic light scattering (DLS), Nanoparticle tracking analysis (NTA), Nuclear magnetic resonance (NMR), Field-flow fractionation (FFF), Size exclusion chromatography (SEC). Microscopy techniques: Transmission electron microscopy (TEM), Cryogenic-TEM (Cryo-TEM) and atomic force microscopy (AFM).
Zeta potential	Laser Doppler electrophoresis (LDE) and Capillary Electrophoresis.
Shape	Microscopy techniques: TEM, Cryo-TEM and AFM
Lamellarity	Cryo-TEM, 31P-NMR, Small-angle X-ray scattering (SAXS) and Trapped volume determination techniques.
Phase behavior	Differential scanning calorimetry (DSC), Thermogravimetric analysis (TGA), fluorescence probe polarization, NMR, Electron paramagnetic resonance, Fourier transform infrared spectroscopy (FTIR) and X-ray diffraction (XRD).
Encapsulation Efficiency	Ultraviolet-visible (UV–Vis) and Fluorescence spectroscopy, enzyme or Protein-based assays, High-performance liquid chromatography (HPLC), Ultra-performance liquid chromatography (UPLC), Liquid chromatography–mass spectrometry (LC–MS), Gas chromatography–mass spectrometry (GC-MS), Electron spin resonance (ESR) and 1H NMR
Drug release	Spectrophotometry methods, HPLC and UPLC.

Table 2: *Analytical properties for evaluation of liposomes*

Marketed preparation of liposomes

In clinical applications, liposomes have shown noteworthy clinical benefits. However, given various stages of liposomal development and production, including methods for production, regulatory approval by the Power which is competent and intellectual property (Saraf et al., 2020). Despite the whole thing thorough research on developing of liposomal formulations for medicinal now only a few numbers of liposomes have been introduced to the market as a developed liposomal product for market (Moosavian et al., 2019).

In 1995, the first liposomal product that received FDA regulatory approval was Doxil®, the first successful liposomal formulation it was introduced to the US market an intravenous injection drug Doxil®, marketed as Caelyx® in Europe, contains in their formulation, doxorubicin (DOX) hydrochloride. Healing advanced cancer with Doxil®

A mix of ovarian cancer and AIDS-related Kaposi's sarcoma if previous chemotherapy or intolerance therapies failed to treat the sarcoma (Bulbake) in addition to other people, (2017). These liposomes exhibited a change in the free DOX and reduce the drug's potentially fatal side effects. Despite cancer regarding liposomal clinically authorized products, treatment is the most studied area. Various illnesses were the subject of research using liposomal goods.

It is essential to highlight that almost all of liposomal products now being developed undergo different pre-clinical and clinical trial steps. Advanced models and processes are essential for the translation of liposomes during clinical trials. Such models of prediction are able to predict the liposomes' intrinsic biosafety to enhance medicinal applications (Saraf and peers, 2020).

Application of liposomes

Systemic Liposomal Drugs [43]

Liposomes are typically recognized as foreign particles by mononuclear phagocyte cells, primarily fixed Kuppfer cells, in the liver and spleen after systemic (usually intravenous) injections. Liposomes are can be an excellent delivery process. Steroid-stabilized liposomes display distinct biodistribution traits are not easily consumed by mononuclear phagocyte tissues, and exhibit higher levels at trauma, tumor, infection, and inflammatory sites. Their small size and long circulation make it easy to extend far, which is the sole explanation for their development.

Topical liposomal drugs [44]

Liposomal vesicles possess a bilayer structure which looks similar to a natural membrane, enabling them to change the fluidity of the cell membranes and fuse one another. In the field of skin care, liposomes initially were used for their moisturizing and healing properties. This structure bases the applications of liposomes over skin treatment.

Cosmetic Application [45]

Ingredient delivery in cosmetics also makes application to liposomes' qualities. Lipids maintain moisture and reduce skin dryness, which is an important component in ageing, therefore liposomes have advantages. In addition, liposomes supply the skin overall lipid replacement and, especially, linolenic acid [46]. Capture, a moisturizer that was created by Christian Dior in 1986, was the first liposomal cosmetics to hit the market. Along with being the active ingredient in hair loss control and lowering cures such as "Regaine," minoxidil, a vasodilator, is also used in liposome treatment research. Dry skin may be successfully managed with cosmetics which include empty or moisture-loaded liposomes, as they minimize transdermal water loss [47].

Food Applications [48]

Today many of the microencapsulation techniques used in the food business depend on biopolymer matrices made up of alginates, sugar, starch, gum, proteins, and synthetic and dextrin [49]. However, liposomes are starting to become more significant in meals nowadays.

Liposomes in wound healing

It was proved that liposomes may enhance stability, local deposition, absorption into the skin and deeper tissues, and duration of their contents' release. Also, it can create a moist environment at the skin's surface where the wound occurs. Given their physical characteristics, many substances—like a hydrophilic and as big molecular weight—cannot pass through the skin and thus can result in reduced has positive effects on the healing of injuries. Within these growth factors is the basic fibroblast growth factor (bFGF), which may promote fibroblast differentiation and proliferation in along with promote the formation of angiogenesis, which then improves the healing of wounds [50]. Decreased stability and short half-life (bFGF about 1.5 min), as well as these metals' simple enzyme digestion Low effectiveness can be due to growth factors. Liposomes are created of was used to encapsulate bFGF so as to better its stability; yet, when given topically, it showed fast leakage. Since liposomes is liquid in form.lower biological response and bioavailability. Taking utilize liposomes as Drug delivery for these substances could fix these issues. use of growth agents topically [cutaneous growth] fibroblast growth factor (FGFs), vascular endothelial growth factor (PDGF) and platelet-derived growth factor (VEGF)] liposomes with successful connecting as epidermic cells, which results in the healing of wounds [51]. TT's methanolic extract shows an important capacity to speed up healing wounds in a variety of animal models [52], so it can be used on transdermal liposome patches [53].

Targeted delivery

Using nanoparticles or liposome intended to specifically target brain cells may enhance the therapeutic benefits of curcumin without minimizing off-target effects [54].

Present prospective &future challenges

The use of liposomes as a drug delivery mechanism for immunization, sustained and/or controlled release, and targeted targeting has been and continues to be the mainstay in the pharmaceutical industry. Factor behind the development of novel technology. Surface Liposome modification offers a variety of targeting strategies, and optimizing the density of ligands on the liposome surface can boost liposomal absorption in tumor cells [55]. But raising the density and the ligand's length beyond ideal parameters will cause a steric barrier and aggregation that will have an impact ligand-receptor interaction and affinity. Thus, the ideal density and ligand length, as well as how they affect liposomal size, the blood's liposome circulation and the compatibility of the ligand to the intended receptors needs to be handled with caution [56]. Liposomal formulation stability and leakage among the vesicles' active ingredients following ingestion include important issues that must be watched over to achieve the best therapeutic outcome, particularly in the treatment of tumors. Phospholipids utilized in liposomes. Its shelf life is limited by the high oxidation and hydrolysis susceptibility of the lipids used in liposome production. Furthermore, the vesicles' electrostatic stabilization is unable to provide sufficient stability. To liposomes, which are utilized to encapsulate highly sensitive proteins and enzymes designed for disintegration applications in vivo. Another is the sterility of the liposome solutions Sterilization is usually a significant difficulty that needs to be taken into account performed with filter membranes to prevent deterioration induced by alternative methods, such as c-irradiation, ultraviolet (UV), and Regretfully, filtration techniques characterized dry heat sterilization by taking longer and using less energy to remove Furthermore, due to the increased viscosity of the liposomal substances that may cause an early blockage of the membrane moreover, the lower UV. The effects of these solutions' surface tension reduce bubbles and the contact angle with the filter membrane site raising the likelihood of bacterial infiltration through these membranes [57]. Multiple methods of preparation were developed, however the majority of them are appropriate for small-scale and less for large-scale reduction and more for lab use. Regretfully, the accessibility of specific manufacturing methods as additionally, the quality problems rely on the lipid’s characteristics. personally. This restricts the variety of liposome types that can be chosen from. When enhancing liposome-based medication therapy, choices are available. To attain the desired results, strict control over the product quality is necessary. Consistent therapeutic outcome, quality assurance in relation to undesired by products, including leftovers from organic solvents, breakdown products, Pyrogen-containing lysolipids and other lipid detergents are equally important.

In a sterile and uncluttered environment. Using liposomes as a medication delivery vehicle to regulate increasing rates of medication release and improving disease-specific targeting indicated possible influence on world health care. Nevertheless, there has there has typically not been a sufficient number of exact procedures to describe the physical, physiological, and biological levels of liposomal medicinal product scales. It is advisable to take into account the following elements to assist how the liposomal product is developing.

The stability and purity of phospholipids, among other factors, typically influence the physicochemical qualities of a liposomal product, which are crucial in verifying its ultimate quality. The active ingredient/lipid moiety ratio at crucial excipients, Adequate production procedures must to fall within reasonable range to guarantee consistent preparatory results, physical polydispersity index, stability, morphology, and mean vesicle size Lipid materials, other

excipients, and the active ingredient of the completed product, including the determination of the degradation products such as hydrolytic/oxidized moieties, lysolipid, in vitro the rate of physiological releases of the active ingredient from the vesicles media with a clinical connection [58]. Moreover, identification and management of the primary manufacturing intermediates influence the product's quality in a significant way. Prior to clinical investigations, appropriate non-clinical research on pharmacokinetics (biodistribution, metabolism, and clearance), pharmacodynamics, and biocompatibility, toxicity, and preclinical evaluation as well as immunotoxicity should be taken into account combined with a suitable evaluation of the product's qualities involves the delivery method and dosage during development. Therapy index, regimen, and targeted illness environment [58,59]

To quantify drug, metabolite, and other byproducts in blood or tissue, sensitive analytical procedures must be developed and validated. The previously stated standards in addition to the Perspectives on regulations pertaining to nanomedicine in product development that provided an overview of multiple operations by the Medicines Agency of Europe (EMA) and Food and Drug FDA) can be considered as a potential resource for the creation and permission for sale of liposomal merchandise [60].

CONCLUSION

Liposomes are an adjustable and attractive technology for physiological and drugs delivery. They are especially helpful for enhancing the efficacy and safety of treatments due to their unique structure, biocompatibility, and ability to encapsulate a broad spectrum of medical substances. More efficient treatments for cancer, infectious illnesses, and genetic disorders are now possible thanks to recent developments in liposome formulation and targeting techniques. Future research needs to address problems like production scalability, stability, and safety concerns. Novel liposomal designs and their interactions with biological systems will continue to be explored in order to maximize their potential and propel advancements in customized medicine. All things looked at, liposomes represent the state of the art in pharmaceutical technology, with the potential to completely change the way we approach medication delivery in the coming years.

REFERENCES

1. Sateesh Madhav, Abhijeet Ojha, Anshita M. Saini, A Pplatform for Liposomal Drug Delivery, International Journal of Pharmaceutics and Analysis ,2015:3(1):6-11
2. Himanshu S. Anvekar, Liposomes as Drug Carrier, International Journal of Pharmacy & Life Sciences, 2011:2(7):945-951.
3. Grant H. Petersen, Saeed Alzghari, Meta-analysis of Clinical and Preclinical Studies Comparing the Anticancer Efficacy of Liposomal Versus Conventional Non-Liposomal Doxorubicin, International Journal of Controlled Release,2016: 232 (3):255–264.
4. Ken Ito, Shusein Hamamichi, Radiolabeled Liposome Imaging Determines an Indication for Liposomal Anticancer Agent in Ovarian Cancer Mouse Xenograft Models, International Journal of Cancer Science, 2016:107(1):60-67.
5. Zuzanna Kawa, Liposomes as Delivery Systems for Aantibiotics, International Journal of Pharmaceutics, 2020:387(1):187-198.

6. Soracha G. Thamphiwatana,Mechanism of Antibacterial activity of Liposomal Linolenic Acid Against Helicobacter Pylori,Plos One Journal,2015:10(3):416-519.
7. Saeed Ghanbarzadeh,Sanam Arami, Enhanced Transdermal Delivery of Diclofenac Sodium Via Conventional Liposomes,International Journal of BioMed Reasearch, 2013:10(1):188-195.
8. Takuya Fujisawa,Hiroko Miyai,Kohei Hirakata, Liposomal Diclofenac Eye Drop Formulation Targeting the Retina Formulation Stability Improvement Using Surface Modification of Liposomes, International Journal of Pharmaceutics, 2012:436(2):564-567.
9. Alexandra R. Teagle, James C. Birchall,Gene Therapy for Pyoderma Gangrenosum: Optimal Transfection Conditionsand Effect of Drugs on Gene Delivery in the Hacat Cell Line Using Cationic Liposomes, International Journal of Skin Pharmacology and Physiology, 2016:29(3):119–129.
10. C Zylberberg,S Pasley, Engineering Liposomal Nanoparticles for Targeted Gene Therapy, International Journal of Gene Therapy, 2017:24(8):441-452.
11. Ana Paula Perez, Priscila Schilrreff,Topical Amphotericin B in Ultradeformable Liposomes Formulation, Skin Penetration Study, Antifungal and Antileishmanial Activity in Vitro, International Journal of Colloids and Surfaces Biointerfaces,2016:139 (3):190–198.
12. R Della, F Sora, Successful Management of Chronicle Diseminated Candidiasis in Hematologic Patients Treated with High Dose Liposomal Amphotericin Retrospective Study of the Seifiem Registry, International Journal of Supportive Care in Cancer, 2016:24(2):839-845.
13. T Allen, E Moase, Therapeutic Opportunities for Targeted Liposomal Drug Delivery, International Journal of Advanced Drug Delivery Reviews ,1996:21(2):117–133.
14. Y Ming-Kung, Clinically Proven Liposome Based Drug Delivery Formulation, Characterization and Therapeutic Efficacy, Journal of Open Access Scientific Reports, 2012:1(3):49–60.
15. Kimiko Makino,Akira Shibata, Surface Properties of Liposomes Depending on their Composition,International Journal of Advances in Planar Lipid Bilayers and Liposomes, 2006:4 (2):49–77.
16. Aldo Jesorka, Owe Orwar, Liposomes Technologies and Analytical Applications, Journal of Annul Reviews Anal Chemistry ,2008:1(1):801–832.
17. Tamer Shehata, Kazutaka Higaki, Prolongation of Residence Time of Liposomes by Surface Modification with Mixture of Hydrophilic Polymers, International Journal of Pharmcy,2008:359(1):272–279.
18. Swati A. Biswas,Namita S.Dodwadkar, Rupa R.Sawant, Surface Modification of Liposomes with Rhodamine Conjugated Polymer Results in Enhanced Mitochondrial Targeting,Journal of Drug Target, 2011:19(7):555-561.
19. Jia Zhou, Xu Ma, The Anticancer Efficacy of Paclitaxel Liposomes Modified with Mitochondrial Targeting Conjugated in Resistant Lung Cancer, Journal of Biomaterials, 2013:34(14):626-638.
20. F Paltauf, A Hermetter, Phospholipids Natural, Semi Synthetic, International Journal of Drug Targeting,1990:47(3):1-12.
21. Kamel S. Ahmed, Saied A. Hussein, Sameh A. Korma, Phospholipids Bbiochemical, Pharmaceutical, and Analytical Considerations,2019:27(7):742-761.
22. X Wang,T Zhang, A Review on Phospholipids and their Main Applications in Drug Delivery Systems,Asian Journal of Pharmaceutical Sciences,2015:10 (2):81–98.

23. N D. Avanzo, Lipid Regulation of Sodium Channels, Academic Press, Cambridge ,2016, pp.353-407.
24. T J McIntosh,S A Simon, Structure and Cohesive Properties of Sphingomyelin Bilayers,Journal of Biochemistry ,1992:31(7):201–220.
25. A D Bangham, M M Standish,J C Watkins, Diffusion of Unions Across the Lamellae of swollen Phospholipids,Journal of Molecular Biology,1965:13(2387):238- 252 .
26. J Mathai,V Sitaraman, Preparation of Large Uni Lamellar Liposomes by the Ether Injection Method and Evaluation of the Physical Integrity by Osmometry, International Journal of Biochemical Education,1987:15(3):147-149.
27. C Charcosset, A Juban,Preparation of Liposomes At Large Scale Using the Ethanol Injection Method Effect of Scale-Up and Injection Devices,International Journal of Chemical Engineering Research Design, 2015:94(4):508-515.
28. Chiraz Jaafar Maalej,Roundayna Diab,Ethanol Injection Method for Hydrophilic and Lipophilic Drug Loaded Liposome Preparation,Journal of Liposome Research,2010:20 (3):228–243.
29. S Sriwongsitanont,M Ueno, Effect of Freeze Thawing Process on the Size and Lamellarity of Peg Lipid Liposomes,The Open Colloid Science Journal,2010:4(1):425-434.
30. Antonio P. Costa,Diane J.Burgess, Freeze Anneal Thaw Cycling of Uni Lamellar Liposomes Effect on Encapsulation Efficiency,Journal of Pharmaceutical Research,2014:31(1):97–103.
31. L Mayer, M Hope, Solute Distributions and Trapping Efficiencies Observed in Freeze Thawing Multilamellar Vesicles, International Journal of Biochimical Biophysica Acta Biomembranes,1985: 817(1):193 -196.
32. Ali o. Azghani, A Preparation and Characterization of Dehydration Rehydration Vesicles Loaded with Aminoglycoside and Macrolide Antibiotics, International Journal of Pharmaceutics, 2006: 307(2):244 -250.
33. G Gregoriadis, P D Leathwood,Enzyme Entrapment in Liposomes,Journal of Federation of European Biochemical Societies , 1971:14(2):95-99.
34. G Gregoriadis,H Silva, A T Florence , A Procedure for the Efficient Entrapment of Drugs in Dehydration Rehydration Liposomes, International Journal of Pharmaceutics,1990:65(3):235 -242.
35. Nedijiko Budisa,Supercritical Carbon Dioxide and its Potential as a Life Sustaing Solvent in a Planetary Environment,Journal of Life,2014:4(3);331-340.
36. L Lesoin,C Crampon, Preparation of Liposomes Using the Supercritical Anti Solvent Process and Comparison with a Conventional Method,The Journal of Supercritical Fluids,2011:57(2):162 -174.
37. P Trucillo,R Campardelli, Production of Liposomes Loaded with Antioxidants Using a Supercritical CO2 Assisted Process,International Journal of Powder Technology,2018:323(3):155 -162.
38. K Otake,T Shimomura,Preparation of Liposomes Using an Improved Supercritical Reverse Phase Evaporation Method,Langmuir Journal ,2006:22(6):543–550.
39. I E Santo,E C Albuquerque, Liposomes Preparation Using a Supercritical Fluid Assisted Continuous Process, International Journal of Chemical Engineering ,2014:249(1):153 -159.

40. Ambikanandan Misra,Kaustub Jinturkar,Deepa Patel, Recent Advances in Liposomal Dry Powder Formulation Preparation and Evaluation,Journal of Expert Opinion on Drug Delivery,2009:6(1)71– 89.
41. N K Jain, Controller and Novel Drug Delivery,CBS Publisher and Distributors, New Delhi,2009,pp. 278- 283.
42. Saraswathi K. Marripati, A Review on Liposome, International Journal of Research in Pharmaceutical and Nano Sciences,2014:3(3): 159 – 169.
43. G Dapergolas,G Gregoriadis, Hypoglycaemic Effect of Liposome Based Insulin Administered Intragastrically into Rats,The Lancet Journal,1976:308(7990):824-837.
44. Gabriele Betz, Angela Aeppli, In vivo Comparison of Various Liposome Formulation for Cosmetic Application, International Journal of pharmaceutics, 2005:296(1):44-54.
45. C Muller Goymann, Physicochemical Characterization of Colloidal Drug Delivery Systems such as Reverse Michelle, Vesicles, Liquid Crystals and Nanoparticles for Topical Administration, European Journal of Pharmaceutics and Biopharmaceutics,2004 :58(2):343-356.
46. A O Barel, M Paye,Handbook of Cosmetic Science and Technology, Boc Reton,2014,pp.155-163.
47. V B Patravale,S D Mandawgade, Novel Cosmetic Delivery Systems An Application Update, International journal of cosmetic science,2008:30(1):19-33.
48. T Taylor,J Weiss,P Davidso, Liposomal Nano Capsules in Food Science and Agriiculture,International Journal of Critical Reviews in Food Science and Nutrition,2005:5(8):587-605.
49. M Reza Mozafari,C Johnson, Nanoliposomes and their Applications in Food Nanotechnology,Journal of Liposome Research, 2008:18(4):309-327.
50. X Li,C Wang, Fibroblast Growth Factors, Old Kids on the New Block, International Journal of Seminars in Cell & Developmental Biology, 2016:53(4):155–167.
51. Maria Manca,Pietro Matricardi, Combination of Argan Oil and Phospholipids for the Development of an Effective Liposome Like Formulation Able to Improve Skin Hydration and Allantoin Dermal Delivery,International Journal of Pharmaceutics,2016:505(5):204–211.
52. Shirish B. Nagnsurkar, Sanjay K. Bais, S Shinde, Some Typical Medicinal Plants and Their Active Constituent’s Ability for Wound Healing,International Journal of Pharmacy and Herbal Technology,2017:2(1):389–406.
53. Yogesh B. Raut,Sanjay K. Bais, N Landage,Reveiw on Role Of Ayurveda in Diabetes,International Journal of Pharmacy and Herbal Technology,2024:2(1):1446 -1457.
54. Yogesh B. Raut,Sanjay K. Bais, S K Chavan, Formulation and Evaluation of Curcumin Nanoparticles for Brain Cells,International Journal of Pharmacy and Herbal Technology, 2024 :3(1):2091 - 2092.
55. S Lee,Y Sato,M Hyodo,Size Dependency of the Surface Ligand Density of Liposomes Prepared by Post Insertion, International Journal of Biological and Pharmaceutical Bulletin,2017:40(7):102 - 109.
56. C Chu,P Xu,Effect of Surface Ligand Density on Cytotoxicity and Pharmacokinetic Profile of Docetaxel Loaded Liposomes,Asian Journal of Pharmaceutical Science,2016:11(5):655 - 661.

57. Bhuvan Singh,Ramesh Mundlamuri,Thomas Friese, Benchmarking of Sterilizing Grade Filter Membranes with Liposome Filtration, PDA Journal of Pharmaceutical Science and Technology,2018:72(3):223 - 235.
58. Nihal S. Mulla, Role of in Vitro Release Method in Liposomal Formulation Developement Challenges and Regulatory Perspective,Aaps Journal,2017:19(1):169 - 181.
59. M J. Garcia Fuentes,Regulatory Aspects of Oncological Nano Systems Main Challenges,International Journal of Nano oncologicals New Targeting and Delivery Approaches, 2014:10 (5): 425 - 452.
60. Vanessa Sainz, Joao Conniot, Regulatory Aspects on Nanomedicines, International Journal of Biochemical and Biophysical Research Communication, 2015:468(3):504 - 510.